Hepatitis Forums

Fatty Liver Disease Main Forums => Nonalcoholic Steatohepatitis (NASH) => Topic started by: Hep Editors on January 11, 2017, 10:13:48 am

Title: Gilead’s Selonsertib Shows Promise as Treatment for NASH
Post by: Hep Editors on January 11, 2017, 10:13:48 am

Gilead Sciences’ selonsertib (formerly GS-4997) improved various measures of liver disease severity among individuals with non-alcoholic steatohepatitis (NASH) and moderate to severe liver fibrosis in a recent midrange trial regardless of whether the drug was given with simtuzumab (SIM).
 
Researchers conducted a randomized, open-label Phase II trial of selonsertib alone or in combination with SIM among 72 people with NASH and fibrosis stages F2 (25 people) or F3 (47 people). Participants were randomized 2 to 2 to 1 to 1 to 1 to receive 24 weeks of 6 milligrams of the investigational apoptosis signal-regulating kinase 1 (ASK1) inhibitor selonsertib, 18 mg of selonsertib, 6 mg of selonsertib plus 125 mg of the monoclonal antibody SIM, 18 mg of selonsertib plus 125 mg of SIM or 125 mg of SIM. Selonsertib was given orally once a day, while SIM was given weekly through a subcutaneous injection (into the fat just below the skin).

For more information...
https://www.hepmag.com/article/gileads-selonsertib-shows-promise-treatment-nash